Microsoft WordPanitumumab Amgen PSD March 2013 FINAL .docx

First Page		Document Content
Date: 2014-10-01 21:56:23 Pharmacology Bristol-Myers Squibb Cetuximab Panitumumab KRAS Bevacizumab Colorectal cancer FOLFIRI Epidermal growth factor receptor Medicine Chemistry Chemotherapy regimens		Microsoft WordPanitumumab Amgen PSD March 2013 FINAL .docx Add to Reading List Source URL: www.pbs.gov.au Download Document from Source Website File Size: 55,80 KB Share Document on Facebook

	TACTIC: Phase 2 trial of panitumumab, cisplatin and gemcitabine in biliary tract cancer The TACTIC trial is helping researchers answer an important health question. It is providing evidence on whether panitumumab (Vectib DocID: 1sxxH - View Document
	AbstractProspective multicenter phase II study of the anti-EGFR (epidermal growth factor receptor) antibody panitumumab (P) in patients with platinum pre-treated, advanced head and neck squamous cell cancer (HNSCC DocID: 1rVAJ - View Document
	ICECREAM: Cetuximab antibody treatment for colorectal cancer with a G13D gene mutation The ICECREAM trial has helped researchers answer an important health question. It has provided evidence that cetuximab alone is not a DocID: 1pJVg - View Document
	PAN01 biomarker poster ESMO 15.pdf DocID: 1pBTA - View Document
	ATTAX3: Panitumumab added to docetaxel, cisplatin, fluoropyrimidine in oesophagogastric cancer The ATTAX3 trial has helped researchers answer an important health question. It has provided evidence on the value of a new c DocID: 1p6wp - View Document